clinical trial · NCT07743983
A Study of BGM0504 in Early T2DM With Obesity
BrightGene Bio-Medical Technology Co., Ltd.·phase3·recruiting·n = 372
Type 2 Diabetes (T2DM)BGM0504semaglutide
brief summary
This trial is conducted in China. The aim is to compare BGM0504 Injection 15 mg with semaglutide 1.0 mg in Chinese T2DM patients with obesity and inadequate control despite diet and exercise. Over 52 weeks of once weekly treatment, efficacy and safety are evaluated, including the rate of diabetes remission at 12 weeks after treatment discontinuation.
started
Aug 30, 2026
primary completion
Sep 30, 2028
completion
Nov 30, 2028
last updated
Aug 4, 2026
official title
A Randomized, Open-Label, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety, and Diabetes Remission of BGM0504 Injection Compared With Semaglutide Injection in Early-Stage Chinese Type 2 Diabetes Mellitus Patients With Obesity and Inadequate Glycemic and Weight Control Despite Diet and Exercise Intervention（BRIGHT-1）
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol